Novo Nordisk raised its full-year outlook for the third time this year on Wednesday, following stronger-than-forecast third-quarter sales of its Wegovy pill.
The results support the Danish drugmaker’s effort to win back ground from US rival Eli Lilly.
Sources: The Business of Fashion.